GeneDx

38 articles about GeneDx

• GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement

  5/22/2023

  GeneDx announced that it had received a letter from The Nasdaq Stock Market LLC stating that, because the Company’s Class A common stock had a closing bid price at or above $1.00 per share for a minimum of ten consecutive business days, the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450, and that the matter is now closed.

• GeneDx Reports First Quarter 2023 Financial Results and Business Highlights

  5/9/2023

  GeneDx Holdings Corp., a leader in delivering improved health outcomes through genomic and clinical insights, reported its financial results for the first quarter of 2023.

• GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option

  5/4/2023

  GeneDx announced the availability of its GenomeXpress® and GenomeSeqDx® whole genome sequencing tests with buccal swabs as an alternative sample collection option for biological parents or other immediate family members.

• GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders

  5/3/2023

  GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, announced a clarification regarding the CUSIP number for the Company’s public warrants.

• GeneDx Announces Reverse Stock Split

  4/28/2023

  GeneDx today announced that its board of directors has approved a 1-for-33 reverse stock split of the Company’s Class A common stock.

• GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023

  4/18/2023

  GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, announced it will release financial results for the first quarter of 2023 after the market closes on Tuesday, May 9, 2023.

• GeneDx Appoints Devin K. Schaffer, J.D., M.B.A, as General Counsel

  4/3/2023

  GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Devin K. Schaffer has been appointed General Counsel, effective April 24, 2023.

• GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”

  3/20/2023

  GeneDx Holdings Corp today announced it is continuing to support whole genome sequencing (WGS) and interpretation services for the GUARDIAN (Genomic Uniform-screening Against Rare Diseases In All Newborns) study.

• GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray

  3/16/2023

  GeneDx Holdings Corp. announced new research at the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting which demonstrates exome sequencing’s diagnostic advantages in shortening patients’ and families’ diagnostic odysseys when compared with chromosomal microarray.

• GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

  3/14/2023

  GeneDx Holdings Corp., a leader in delivering improved health outcomes through genomic and clinical insights, reported its financial results for the fourth quarter and full year ended December 31, 2022.

• GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference

  3/1/2023

  GeneDx today announced that company management will participate at the Cowen 43rd Annual Healthcare Conference in Boston, MA.

• GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting

  2/28/2023

  GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced its contributions to eight posters, one platform presentation and one symposium session to be released at the upcoming 2023 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.

• GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023

  2/21/2023

  GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the fourth quarter and full year of 2022 after the market closes on Tuesday, March 14, 2023.

• GeneDx Announces Closing of Underwritten Public Offering and Concurrent Registered Direct Offering

  1/31/2023

  GeneDx Holdings Corp. announced the closing of its previously announced underwritten public offering of shares of its Class A common stock and concurrent registered direct offering of shares of its Class A common stock.

• GeneDx Holdings Announces Pricing Of A $150 Million Underwritten Public Offering Of Class A Common Stock And Concurrent Registered Direct Offering

  1/27/2023

  GeneDx Holdings Corp. (Nasdaq: WGS) today announced the pricing of offerings for an aggregate of 428,571,429 shares of its Class A common stock at a public offering price of $0.35 per share (the “Offerings”).

• GeneDx Announces Proposed Underwritten Public Offering of Class a Common Stock and Concurrent Registered Direct Offering

  1/26/2023

  GeneDx Holdings Corp., a leader in delivering improved health outcomes through genomic and clinical insights, announced that it intends to commence an underwritten public offering of its Class A common stock.

• Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

  1/9/2023

  Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis ® platforms.

• Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms

  5/2/2022

  Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it has completed the acquisition of GeneDx, LLC (“GeneDx”), a leader in genomic testing and analysis for rare disorders, from OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”).

• Study of More Than 18,000 Patients Finds Exome Sequencing Delivers Higher Diagnostic Rates for Autism Spectrum Disorders

  4/26/2022

  GeneDx, LLC, a leader in genomic analysis, unveiled new data demonstrating positive outcomes of exome analysis for individuals with autism spectrum disorders, supporting the use of a broader genetic testing approach to diagnose ASD.

• 

  Rapid Whole Genome Sequencing in Infants Could Even Playing Field for Treatment

  4/11/2022

  What if infants with genetic illnesses could be diagnosed in a matter of days? New research surrounding rapid whole genome sequencing suggests that soon, they could be.